Harvard Bioscience, Inc. (HBIO) - Forward Price-to-Revenue Multiple

Harvard Bioscience Inc. (HBIO) - corporate logo

Harvard Bioscience is implementing eco-friendly production standards, reducing its carbon footprint and costs. Stable demand from laboratories ensures resilience against crises. GURU.Markets analytics provide a forward-looking P/S valuation, where 0.50 serves as the current parameter value. Global diversification of assembly across the US and EU minimizes geopolitical risks, supporting the operational stability of the business.

HBIO harvardbioscience.com: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/13/2026

harvardbioscience.com - analytical breakdowns and key metrics (HBIO)

- market price and analyst price targets:
Price Chart Harvard Bioscience|HBIO - Fair Value Consensus
- market capitalization indicators:
Market Valuation Harvard Bioscience, Inc.|HBIO - Enterprise Value
- business book valuation details:
Net Assets per Single Share Harvard Bioscience|HBIO - Company Net Assets|Market Capitalization to Book Value Ratio harvardbioscience.com|HBIO - Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Harvard Bioscience|HBIO - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Harvard Bioscience, Inc.|HBIO - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Harvard Bioscience, Inc.|HBIO - Long-Term Debt Volume|Company Short-Term Debts Harvard Bioscience|Quick Ratio harvardbioscience.com
- business earnings and investment ratios data:
HBIO - Net Profit|Expected Profit Harvard Bioscience|HBIO - Company Value to Net Income|Projected Price to Earnings Harvard Bioscience|HBIO - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Harvard Bioscience, Inc.|HBIO - Operating profit EBITDA|Earnings per share for the last twelve months Harvard Bioscience|HBIO - Earnings per share for the trailing year|Quarterly EPS earnings growth harvardbioscience.com|HBIO - Earnings per share growth this year|Expected earnings per share growth for next year Harvard Bioscience
- sales and revenue data:
HBIO - Company Sales Revenue|Projected Sales Volume Harvard Bioscience, Inc.|HBIO - Price-to-Revenue Ratio|Forward P/S Multiple Harvard Bioscience, Inc.
General company analysis:HBIO (Harvard Bioscience)
Original product of Harvard Bioscience Inc.

This indicator determines the market value of a unit of expected revenue, allowing investors to assess future business growth rates between official reports. When analyzing the forward price-to-sales ratio, one must consider the dependence of Harvard Bioscience (HBIO) on the volume of government science funding in the US and Europe, as a reduction in grants directly diminishes the fundamental attractiveness of expected sales.

Analysis of competing companies

Price-to-Projected Revenue Ratio Intuitive ISRG|Forward Price to Sales DHR|BDX: Forward Price-to-Revenue Multiple|STE - Forward P/S Multiple|West Pharmaceutical Services (WST) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple baxter.com|MASI (Masimo) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stevanato Group SpA STVN|Price-to-Projected Revenue Ratio Teleflex Inc (TFX)|Merit Medical Corp - Market Cap to Projected Revenue|Envista Holdings - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ICUI (icumed.com)|XRAY - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio LeMaitre Vascular Inc LMAT|ATRC: Forward P/S Multiple|STAAR Surgical Co - Forward Price to Sales|NAGE (ChromaDex Corporation) - Forward P/S Multiple|Forward P/S Multiple zimvie.com|Price-to-Projected Revenue Ratio AngioDynamics (ANGO)|CERS (Cerus Corp.) - Forward Price to Sales|Alpha Teknova Inc - Forward Price-to-Revenue Multiple|Monogram Orthopedics Inc. - Price-to-Projected Revenue Ratio|Sharps Tech - Forward P/S Multiple|INFU - Forward P/S Multiple|Utah Medical Products, Inc. (UTMD) - Price-to-Projected Revenue Ratio|KORU Medical - Forward Price to Sales|NYXH (Nyxoah, S.A.) - Forward P/S Multiple|Market Cap to Projected Revenue MBOT (Microbot Medical, Inc)|Forward Price-to-Revenue Multiple PDEX (Pro-Dex, Inc.)|ZTEK (zentek.com) - Forward Price to Sales|Forward P/S Multiple ELUT (Elutia)|Milestone Scientific Inc - Price-to-Projected Revenue Ratio|NEXGEL, Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Retractable Technologies RVP|Femasys Inc. (FEMY) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Meihua Medical Technologies Co., Ltd. (MHUA)|Price-to-Projected Revenue Ratio Predictive Oncology Inc|Callan JMB Corp (CJMB) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ATRI|Forward Price-to-Revenue Multiple NeuroMetrix Corporation NURO